14 results about "Mass cytometry" patented technology

Disclosed is a method of differentiating empty capsids from full capsids or loaded and unloaded non-viral gene therapy vectors in a viral preparation. The method comprises the steps of: a) providing a preparation of viral particles or gene therapy vectors; b) subjecting the preparation to interferometric scattering mass cytometry (ISCAMS) in an interferometric scattering microscope to generate mass distribution data of the viral particles; c) determining from the mass distribution data the level of empty capsids and capsids containing genomes or the level of loaded and unloaded vectors in the viral particles.

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to mass tags and additional reagents to reduce background and / or maintain target binding of mass tagged specific binding partners (SBPs), and schemes for associating a plurality of mass tags with a single SBP. As such, embodiments include any combination of one or more reagents and their use. The reagents, kits and methods herein may be used for mass cytometry, including imaging mass cytometry. In some aspects, reagents, kits or methods may be used for delivery of a large number of radioisotopes to a target analyte, for example for therapeutic use or radiometric detection. In certain aspects, only non-radioactive isotopes may be used for mass cytometry.

Inductively coupled plasma (ICP) analyzers use an ICP torch to generate plasma in which the sample is atomized and ionized. Analysis of the atomic ions can be performed using atomic analysis, such as mass spectrometry (MS) or atomic emission spectrometry (AES). Particle-based ICP analysis involves analyzing particles (e.g., cells, magnetic beads, or laser ablation plumes) by atomizing and ionizing them in an ICP torch chamber followed by atomic analysis. In mass cytometry, the mass tags of the particles are analyzed using mass spectrometry, such as ICP-MS. The systems and methods of this application include one or more of the following: a removable ICP torch holder assembly, an external ignition device, an ICP induction coil including annular fins, a particle-suspended sample introduction jet, and its ICP analyzer.

This invention provides a mass tag for mass flow cytometry, its preparation method, and its application. The mass tag provided by this invention has the chemical structure shown in Formula 1. The compound shown in Formula 1 provided by this invention offers a new channel for CyTOF single-cell analysis, suitable for the detection of various biomarkers such as live cells and proteins. It is of great significance for more in-depth and comprehensive analysis of changes in various cell subtypes and their proportions, and for predicting the changing trends of clinical disease courses, showing good clinical application prospects and significant social benefits.

The embodiment of the invention discloses a disinfection cleaning solution for a mass spectrometry flow cytometer and a preparation method of the disinfection cleaning solution. The disinfection cleaning solution is prepared from the following raw materials in percentage by weight: 0.1%-0.5% of trypsin, 0.1%-0.5% of IV type collagenase, 0.1%-0.5% of I type collagenase, 0.1%-1% of DNA enzyme, 0.1%-0.5% of protease, 0.01%-0.05% of EDTA (Ethylene Diamine Tetraacetic Acid), 0.1%-2% of a surfactant disinfectant and the balance of deionized water. When the disinfection cleaning solution is used for cleaning a key component glass atomizer of a mass spectrometry flow cytometry, residual components, including collagen, extracellular matrix, histone, DNA and the like, possibly existing in the using process can be effectively digested and enzymolyzed, and the disinfection cleaning solution has an excellent cleaning effect.

The invention provides a reagent composition for detecting whole-blood-method myeloid-derived suppressor cells through mass spectrum flow cytometry and application of the reagent composition. The reagent composition comprises three groups of reagents and is a flow cytometry detection composition capable of being used for detecting whole-blood-method myeloid-derived suppressor cells through mass spectrometry flow cytometry, when the reagent composition is applied, 21 reagents are used in a single tube at the same time, and the three groups of reagents are added in sequence and used for a sample in the same tube. The reagent provided by the invention can be applied to mass spectrometry flow cytometry to detect whole-blood-method myeloid-derived suppressor cells and evaluate whether a detected sample has a myeloid suppression state or not.

A method for constructing a diagnostic model for distinguishing between benign and malignant pulmonary nodules on the basis of a single-cell immune profile, which method comprises: obtaining PBMCs from a peripheral blood sample, and performing mass cytometry analysis on the PBMCs to obtain a mass cytometry analysis dataset; classifying cells into different phenotypes on the basis of marker expression and by using a PARC clustering algorithm; and using the expression proportion of each cell subgroup as modeling features to obtain a diagnostic model for distinguishing between benign and malignant pulmonary nodules, thereby realizing the screening and early diagnosis of lung cancer. The model features non-invasiveness, high sensitivity and high specificity, improves the diagnostic accuracy of lung cancer screening, and provides patients with earlier treatment opportunities and more suitable surgical approaches.

Methods that include tagging at least one cell with a MXene, the cell optionally being an immune cell; and detecting at least one component of the MXene using one or more of single-cell mass cytometry by time-of-flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging (MIBI-TOF). Systems that include a cell tagged with an amount of a MXene; and a detection train configured for at least one of time of flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging by time-of-flight (MIBI-TOF) that detects the MXene. Methods that include tagging a population of cells with at least one MXene: and processing the population of cells with at least one of time-of-flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging by time-of-flight (MIBI-TOF) that detects the at least MXene; and relating the detection of the at least one MXene to a characteristic of the population of cells.

To provide systems and method for imaging mass spectrometry, including imaging mass cytometry.SOLUTION: Apparatus and method for imaging mass spectrometry (IMS) that improve speed of sample acquisition, signal sensitivity, and / or signal stability may minimize the transfer time of and / or the spread of plume of a sample material removed from a sample to be transferred to components of the imaging mass spectrometer or mass cytometer that ionize and analyze the sample material.SELECTED DRAWING: Figure 1

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to the mass tags, and additional reagents to reduce background and / or preserve specific binding partner (SBP) binding of the mass label, as well as protocols for associating multiple mass tags with a single SBP. Thus, embodiments include any combination of one or more reagents and uses thereof. The reagents, kits, and methods herein are useful in mass cytometry, including imaging mass cytometry. In some aspects, the reagents, kits, or methods are useful for delivering a large number of radioisotopes to a target analyte, e.g., for therapeutic use or radioimaging. In certain aspects, only non-radioactive isotopes are used in mass cytometry.

The invention discloses a polymer metal chelating tag for mass spectrometry flow cytometry as well as a preparation method and application of the polymer metal chelating tag. The structural general formula of the polymer metal chelating label is nDOTA-PEG-Linker, and the structural general formula of the polymer metal chelating label is nDOTA-PEG-Linker. Wherein DOTA represents a polypeptide chain segment containing DOTA, n represents the number of DOTA chelating units accurately introduced through solid-phase polypeptide synthesis, and n is an integer ranging from 4 to 16; pEG is polyethylene glycol as a spacer group, the mobility of a peptide chain can be improved by a flexible chain, the accessibility of Linker is improved, and the reaction efficiency is improved; linker refers to a group capable of being directionally coupled with an antibody. The reagent label prepared by adopting an automatic solid-phase synthesizer is accurate and small in molecular weight, simple and convenient in synthesis steps, capable of chelating various metal elements including lanthanide metals and other heavy metals, and capable of efficiently labeling an antibody due to small steric hindrance, and the labeled antibody has high specificity and high sensitivity and can be used for mass spectrum flow type detection.

The invention relates to the technical field of medical biology, in particular to a living tumor heterogeneity analysis method combining elastic ultrasound and a mass spectrum flow technology, which comprises the following steps: firstly, carrying out heterogeneity detection on living tumor tissues based on an elastic ultrasound imaging technology to obtain an elastic ultrasound imaging result; and then, based on an elastic ultrasonic imaging result, screening tumor specimens in different development stages, and analyzing immune cell composition and heterogeneity characteristics of the tumor specimens by adopting a mass spectrum flow type technology. According to the living tumor heterogeneity analysis method combining the elastic ultrasound and the mass spectrum flow technology, positioning and qualitative detection are carried out on tumor primary lesions through the elastic ultrasound imaging technology, and multi-primary-lesion tumor cell immune microenvironment characteristics are analyzed in combination with the mass spectrum flow technology.

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to mass tags and additional reagents to reduce background and / or maintain target binding of mass tagged specific binding partners (SBPs), and schemes for associating a plurality of mass tags with a single SBP. As such, embodiments include any combination of one or more reagents and their use. The reagents, kits and methods herein may be used for mass cytometry, including imaging mass cytometry. In some aspects, reagents, kits or methods may be used for delivery of a large number of radioisotopes to a target analyte, for example for therapeutic use or radiometric detection. In certain aspects, only non-radioactive isotopes may be used for mass cytometry.

The methods, compositions and kits described herein provide signal amplification approaches for the detection of target biomolecules that significantly increase the sensitivity of detection using target-binding ligand molecules. The methods include cyclic addition of nucleic acid repeats to, e.g., target-binding molecules, thereby providing multiple landing pads for labeled probes. The methods are well-suited to performance in multiplex, thereby permitting the sensitive detection of multiple targets in a single assay. These methods and compositions can be applied to, among other things, imaging, flow cytometry, and mass cytometry / Cy TOF. providing additional tools for research and diagnostic purposes.